Results 241 to 250 of about 103,745 (353)
Postdiagnosis Smoking Cessation and Survival Outcomes of Head and Neck Cancer Patients
ABSTRACT Background Post‐diagnosis smoking remains prevalent among head and neck squamous cell carcinoma (HNSCC) patients. Smoking cessation may improve patient outcomes. Methods A prospective longitudinal cohort study (2008–2014) included 835 newly diagnosed HNSCC patients and followed up for 7 years. Participants were categorized by smoking behavior (
Elham Mohebbi+11 more
wiley +1 more source
Otorhinolaryngology and Artificial Intelligence
openaire +4 more sources
Current Applications and Outcomes of Robotic Surgery in Pediatric Upper Airway and Neck Procedures: A Systematic Review. [PDF]
Visconti IC+6 more
europepmc +1 more source
ABSTRACT Background Head and neck cancer (HNC) significantly impacts older adults, with mortality influenced by multiple factors. The Multidimensional Prognostic Index (MPI), derived from comprehensive geriatric assessment (CGA), may improve risk stratification and clinical decision making. Methods An observational cohort study was conducted at Erasmus
Ajay T. Bakas+5 more
wiley +1 more source
Correction: Rotterdam Oncology Documentation (RONCDOC) - a high-quality data warehouse and tissue collection for head and neck cancer. [PDF]
Hoesseini A+11 more
europepmc +1 more source
ABSTRACT Objective Oral cavity carcinomas (OCCs) represent roughly 50% of all head and neck cancers. The risk of occult neck metastases for early‐stage OCCs ranges from 15% to 35%, hence the need to develop tools that can support the diagnosis of detecting these neck metastases.
Stefania Troise+12 more
wiley +1 more source
ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care. [PDF]
Conti DM+8 more
europepmc +1 more source
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after ...
Tomomi Sanomachi+16 more
wiley +1 more source